Clinical hold lifted for diabetes program, CFO appointed, increased cash position, R&D expenses noted

From GlobeNewswire: 2025-03-20 17:35:31

Clinical hold has been lifted for vTv Therapeutics’ cadisegliatin program for diabetes, allowing the Phase 3 trial for type 1 diabetes patients to resume in Q2 2025. Martin Lafontaine has been appointed as Chief Commercial Officer to strengthen the company’s commercial leadership. Financial results for the fourth quarter and full year 2024 show an increase in cash position to $36.7 million as of December 31, 2024, compared to $9.4 million in 2023. R&D expenses were $2.2 million for Q4 2024, with a net loss of $3.6 million for the same period. For the full year 2024, R&D expenses were $11.5 million, with a net loss of $18.5 million. Cadisegliatin is a liver-selective glucokinase activator being investigated as an adjunctive therapy to insulin for T1D.



Read more at GlobeNewswire: vTv Therapeutics Announces 2024 Fourth Quarter and Full